New vaccine targets Hard-to-Treat EBV cancers
NCT ID NCT07532746
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called KSD-101 in 55 people with relapsed or refractory EBV-associated blood cancers. The vaccine is designed to train the immune system to attack cancer cells infected with the Epstein-Barr virus. The main goals are to check safety and see if the vaccine can shrink tumors or improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KSD-101 (dendritic cell vaccine)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with EBV-related blood cancers that have not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 55 participants, so safety and effectiveness are not yet known. The vaccine may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY EBV-ASSOCIATED HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China